3/18/2013

States should not put obstacles in the way of the development of biosimilars that the FDA deems interchangeable with original biologics, according to this editorial. Before acting, state lawmakers should wait to see the FDA's biosimilar guidance, particularly requirements for monitoring side effects.

Related Summaries